The "Dividend King" With Royal Ambitions – Why Just 11 Years of Growth Is Enough for the Title
Here’s how the Abbott spin-off earned this status and why its dividend policy is a gold standard for reliability.
MaxDividends Mission: Helping & Supporting Everyone in Building a Growing Passive Income, Retiring Early, and Living Off Dividends.
For dividend investors seeking opportunities with strong growth potential, MaxDividends Stock Ideas offers a daily, in-depth look at companies worth considering for a dividend portfolio.
Scroll Down to Read. No access yet? Check your status & upgrade to Premium to join the movement. Exclusive insights await inside!
Intro
💡 Invest in companies you believe in - W. Buffett
When discussing "Dividend Kings"—companies with decades of consistent payout growth—AbbVie (ABBV) is frequently mentioned alongside legends like Coca-Cola and Johnson & Johnson.
But there’s a catch: Officially, the company has raised its dividend for just 11 consecutive years, far fewer than traditional royalty. Yet AbbVie didn’t earn this title by accident.
After spinning off from Abbott Laboratories in 2013, it inherited part of its parent’s dividend legacy and went on to build an empire around blockbusters like Humira, Skyrizi, and Rinvoq. Why do investors overlook the "youth" of its dividend program, and what’s the secret behind Wall Street’s confidence? Let’s dive in.
History of the Company
AbbVie is a global biopharmaceutical company that was officially established in 2013 when it separated from its parent company, Abbott Laboratories. However, its roots trace back to Abbott's founding in 1888 by Dr. Wallace C. Abbott.
Originally focused on producing pharmaceutical formulations, Abbott grew into a diversified healthcare giant over the decades. In 2013, Abbott decided to spin off its research-based pharmaceuticals division to create AbbVie, allowing both companies to focus on their respective specialties.
AbbVie inherited a strong portfolio, including the blockbuster drug Humira (adalimumab), which became the world's top-selling medication for autoimmune diseases. Since its independence, AbbVie has expanded through strategic acquisitions, such as Pharmacyclics (2015) and Allergan (2020), strengthening its presence in oncology, neuroscience, and aesthetics.
Today, AbbVie remains a leader in innovative therapies, driven by its commitment to addressing complex health challenges.
A Proven Dividend King👑
While AbbVie (NYSE: ABBV) has officially increased its dividends for only 11 consecutive years since becoming an independent company in 2013, it holds the prestigious Dividend King title—a distinction typically reserved for companies with 50+ years of uninterrupted dividend growth.
This seeming contradiction stems from AbbVie’s deep-rooted history as part of Abbott Laboratories (ABT), which has raised dividends for over 50 years and is itself a Dividend King.
Why AbbVie Qualifies as a Dividend King
Legacy of Abbott’s Dividend Streak
AbbVie was spun off from Abbott in 2013 but inherited its dividend-paying DNA.
Abbott has 52+ years of dividend growth, and AbbVie’s payouts are effectively a continuation of that legacy.
The Dividend Kings list recognizes companies with 50+ years of increases, and since AbbVie’s dividends stem from Abbott’s unbroken record, it retains the title.
Aggressive Dividend Growth Post-Spin-Off
Since 2013, AbbVie has raised dividends at an average annual rate of ~8%, outpacing many peers.
The current yield stands at ~3.7%, with a quarterly payout of $1.64 per share (as of 2024).
Even with Humira’s patent expiration, AbbVie has maintained strong cash flow, supporting dividend sustainability.
Strategic Acquisitions & Pipeline Strength
AbbVie has diversified beyond Humira via acquisitions (e.g., Allergan, Pharmacyclics, Cerevel Therapeutics) and new blockbusters like Skyrizi and Rinvoq, projected to generate $27B+ annually by 2027.
Its R&D pipeline (80+ clinical programs) and recent FDA approvals (e.g., epcoritamab for blood cancer) ensure long-term growth.
🦅 Dividend Eagles
An updated compilation of 100+ top-performing dividend stocks with 15+ years of consecutive dividend increases, selected based on MaxDividends’ strict criteria.
Companies featured on the Dividend Eagles list have a proven track record of regular and increasing dividend payouts. This ensures you receive a reliable income, whether you're planning for retirement or seeking additional cash flow.
The Dividend Eagles list offers precisely that—a gateway to financial growth and stability.
Beyond dividends, these companies often exhibit strong fundamentals and growth prospects. Investing in them not only provides income but also the opportunity for your investment to grow over time.
This is how we build our own growing passive income and long-term wealth.
Key Institutional Investors in AbbVie
AbbVie (NYSE: ABBV) attracts significant investment from major institutional players, reflecting its stability as a dividend powerhouse and growth potential in biopharma. As of recent filings, top shareholders include Vanguard Group (holding ~8.2% of shares), BlackRock (~7.5%), and State Street Global Advisors (~4.1%).
These asset managers highlight AbbVie’s appeal for long-term portfolios due to its robust cash flow and dividend consistency. Hedge funds also maintain positions, with 41 funds reporting stakes in Q1 2025, though specific allocations vary based on market sentiment toward AbbVie’s post-Humira transition.
Notably, insider ownership remains minimal, emphasizing institutional dominance in shaping ABBV’s market dynamics. For detailed holdings, investors track 13F filings via platforms like Eulerpool.
What Makes AbbVie Stand Out?
AbbVie (NYSE: ABBV)
Financial Score: 91 / 99 ⭐️⭐️⭐️⭐️
Industry: Drug Manufacturers - General
👉 Learn more about Financial Score
AbbVie is a global biopharmaceutical company specializing in the development and production of innovative drugs in the fields of immunology, oncology, neurology and aesthetic medicine. It is best known for Humira, the world's best-selling drug for the treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, etc.).
After the expiration of the patent for Humira, AbbVie is actively developing new blockbusters such as Skyrizi and Rinvoq, and also strengthening the portfolio through strategic acquisitions (Allergan, Pharmacyclics).
The company is among the Dividend Kings due to its long-standing history of increasing dividends (the legacy of Abbott Laboratories) and remains a key player in the pharmaceutical market.
AbbVie - Quick MaxDividends Team Overview
🟢 Current reporting data indicates that the company is profitable.
🟢 The company continues to confidently increase sales volumes, which is a good sign of stability
🟢 Growing operating profit over recent years is a good indicator of the effective management of the company in recent years.
🟢 Earnings per share have a positive trend and are growing. This is a good sign of healthy business
🟢 The company has an excellent position in the market, it has been generating income and demonstrating profitability for many years, even in difficult yearsFinancial Statement
If you want to stay on top of your portfolio's health, don't forget to check in on the financials of the companies you've invested in. The better shape they’re in, the better your results will be. Keep an eye on their quarterly and annual reports to see how they're performing.
Here is a quick dive into AbbVie over last years
The strongest and most stable companies tend to have a Financial Score of 80+, with the very best ones hitting 90+. If you see that score start to dip below 80, that’s your cue to consider jumping ship before things get worse.
👉 Learn More about Financial Score
Our Paid Members get access to a curated watchlist of 19,000 companies worldwide, all scored by our team on a regular basis. Companies like AbbVie are on that list, too.
Future Growth Prospects for AbbVie
AbbVie’s future growth is anchored in its strategic diversification beyond Humira, with strong momentum from next-generation immunology drugs Skyrizi and Rinvoq, projected to generate $31B+ in combined sales by 2027.
The company is expanding into oncology with promising pipeline assets like ABBV-969 (a dual-targeted ADC for prostate cancer) and ABBV-514 (a CCR8-targeting antibody for solid tumors), showcasing innovation in hard-to-treat cancers.
Additionally, AbbVie is investing $10B in U.S. manufacturing over the next decade, including capacity for obesity drugs following its partnership with Gubra. Neuroscience remains a key focus, with late-stage candidates for Parkinson’s and Alzheimer’s psychosis, while Allergan Aesthetics drives growth via expanded training centers and product adoption.
Despite near-term risks like tariff impacts and biosimilar competition, AbbVie’s high single-digit revenue CAGR forecast through 2029 and robust pipeline position it for sustained leadership in biopharma.
Key Drivers:
Immunology dominance (Skyrizi/Rinvoq)
Oncology & neuroscience breakthroughs
Obesity & aesthetics expansion
Manufacturing & R&D investments ($10.8B in 2024).
AbbVie Financial Performance
AbbVie demonstrated strong financial performance in Q1 2025, with global net revenues reaching $13.34 billion, an 8.4% increase YoY (9.8% operationally), driven by robust growth in its immunology and neuroscience portfolios.
The company's adjusted diluted EPS rose 6.5% to $2.46, despite a $0.13 per share headwind from acquired IPR&D expenses. Key growth drivers included Skyrizi ($3.43B, +70.5% YoY) and Rinvoq ($1.72B, +57.2% YoY), which helped offset declining Humira sales ($1.12B, -50.6% YoY).
Neuroscience revenues grew 16.1% to $2.28B, led by Botox Therapeutic ($866M) and Vraylar ($765M), while oncology sales increased 5.8% to $1.63B, supported by Venclexta ($665M). However, the aesthetics segment declined 11.7% to $1.10B due to softer demand for Botox Cosmetic and Juvederm.
AbbVie raised its full-year 2025 adjusted EPS guidance to $12.09–$12.29, reflecting confidence in its diversified portfolio and pipeline. Despite a GAAP net income decline (-29.2% CAGR over 3 years), the company maintains strong cash flow, supporting its dividend growth (3.26% yield) and strategic acquisitions.
Abbvie Dividends Status
With MaxDividends, it's easier than ever to access top dividend companies, track your results, and explore new dividend ideas.
The MaxDividends Top Stocks List features ~100 of the most reliable dividend companies in the U.S. market, each with 15+ years of consecutive dividend increases. These stocks are carefully selected based on MaxDividends' strict criteria for consistency and reliability.
Dividend Kings represent the elite tier of dividend growth stocks. With 50+ years of consecutive dividend increases, these companies offer unparalleled income stability, making them a top choice for investors seeking long-term reliability in an unpredictable market.
With 25+ years of consecutive dividend increases, Dividend Aristocrats are among the strongest dividend growth stocks. These companies have a proven track record of not only maintaining but consistently increasing their dividends, often outperforming the broader market over time.
Why Invest in AbbVie?
AbbVie (NYSE: ABBV) is a compelling investment due to its strong dividend track record, diversified drug portfolio, and robust pipeline. As a Dividend King, AbbVie has raised payouts for 12 consecutive years (extending Abbott Laboratories’ 50+ year legacy), offering an attractive 3.4% yield. The company has successfully navigated Humira’s patent cliff with Skyrizi and Rinvoq, projected to generate $31B+ in combined sales by 2027, ensuring revenue growth.
Additionally, AbbVie is expanding in oncology (e.g., Epkinly, ABBV-969) and neuroscience, with a $10B U.S. manufacturing investment to support future innovations. Analysts forecast high single-digit revenue growth through 2029, backed by strategic acquisitions (Allergan, ImmunoGen) and a late-stage pipeline targeting obesity, Alzheimer’s, and Parkinson’s. With a P/E of 14.4x (2025 earnings) and a history of outperforming the S&P 500, AbbVie balances income stability and growth potential.
Key Reasons:
✅ Reliable dividends (3.4% yield, 12-year growth streak)
✅ Post-Humira success (Skyrizi, Rinvoq driving revenue)
✅ Expanding pipeline (oncology, neuroscience, obesity drugs)
✅ Undervalued growth (P/E below sector average)
For long-term investors, AbbVie offers a rare mix of defensive income and biotech upside.
Interesting Fact
Humira, AbbVie's flagship drug, was the world's best-selling drug from 2012 to 2023, generating $20+ billion in annual revenue for the company — more than many pharmaceutical companies combined. AbbVie was able to cushion the impact of Humira's patent expiration with new drugs (Skyrizi and Rinvoq), which are already generating $11+ billion a year and growing.
Competitors
1. Johnson & Johnson (NYSE: JNJ)
Financial Score: 97 / 99
Industry: Drug Manufacturers - General
Johnson & Johnson (J&J) is one of the world's largest multinational healthcare corporations, founded in 1886. The company operates across three core segments: pharmaceuticals (cancer treatments, immunology, and infectious disease drugs), medical devices (surgical equipment, diagnostics), and consumer health (iconic brands like Neutrogena, Listerine, and Tylenol).
J&J is renowned for its reliable dividend track record, being a Dividend King with over 60 consecutive years of payout increases. The company also gained global recognition for developing one of the first COVID-19 vaccines and maintains a presence in more than 150 countries. Its diversified portfolio and long-standing innovation make J&J a leader in the healthcare industry.
2. Merck & Company Inc (NYSE: MRK)
Financial Score: 98 / 99
Industry: Drug Manufacturers - General
Merck & Co., Inc. (known as MSD outside North America) is a leading global biopharmaceutical company founded in 1891. The company develops innovative medicines, vaccines, and animal health products, with key focus areas including oncology (Keytruda), vaccines (Gardasil), infectious diseases, and cardiometabolic disorders.
Merck is best known for Keytruda (pembrolizumab), a blockbuster immunotherapy drug that has transformed cancer treatment. With a strong R&D pipeline and a history of scientific breakthroughs, Merck remains at the forefront of medical innovation while maintaining a commitment to global health initiatives. The company operates in over 140 countries and is a component of the Dow Jones Industrial Average.
Final Thoughts: Should We Buy AbbVie?
AbbVie (ABBV) presents a compelling investment case for both income-focused and growth-oriented investors. On the dividend front, its 3.4% yield and 12-year growth streak (extending Abbott’s 50+ year legacy) make it a rare Dividend King with reliable payouts.
Financially, the company has successfully navigated Humira’s patent cliff, with Skyrizi and Rinvoq now driving revenue ($11B+ annually) and oncology/neuroscience pipelines (e.g., Epkinly, Vraylar) offering future growth.
Verdict: Add to watchlist for long-term investors seeking dividend stability + biotech growth, but monitor pipeline execution and debt levels ($60B).
Current Market Value
Undervalued \ Overvalued \ Fairly Valued
Compare the P/E ratios of competitor companies to assess whether the stock you're considering is overvalued. We calculate the average P/E among competitors as a benchmark.
If a company's current P/E is 20% or more below the competitor average, it is considered undervalued.
If it is 20% or more above, it is considered overvalued.
The P/E ratio is calculated by dividing the market value per share by earnings per share (EPS).
Abbvie Current Value - Overvalued
Analysts Consensus
Analyst sentiment toward AbbVie remains overwhelmingly positive, with 28 Strong Buy and 13 Buy recommendations, reflecting confidence in the company's growth trajectory.
In contrast, only 12 analysts recommend Hold, while Underperform/Sell ratings are minimal (11 total), signaling broad market optimism.
Price targets further support this outlook, with an average target of $208.86 (18% upside from the current $188.47), and a bullish high target of $250.00 (33% potential gain).
The consensus suggests AbbVie is well-positioned to capitalize on its immunology leadership (Skyrizi/Rinvoq) and pipeline catalysts, though investors should weigh execution risks against its attractive valuation and dividend appeal.
To your wealth, MaxDividends Team
More Dividend Ideas
Scroll Down to Read. Don’t have access? Check Your Paid Status & Upgrade to Premium.
Don’t have access? Check Your Paid Status & Upgrade to Premium.
⭐️ ⭐️⭐️⭐️⭐️
MaxDividends is a Bestseller on Substack!
Hundreds of premium members have already discovered the benefits of the community and app, earning passive income through dividends with MaxDividends. Their passive income keeps growing!
We Are Already Recommended by Our Community
Russell - "Want to get caught up with your portfolio so far and follow along until we can all retire. "
Todd - "Just found this site --excited to get started!"
Vinny - "Helping retail investors retire early and comfortably "
And Many Others
“You are serious and trustwhorty”
“Developing an additional source of retirement income.”
Thought I would share - I was able to create an Ultra High Dividend portfolio w/15 companies today that would net me a $4,200+/month income. I just retired this month and have a current income of $10,230/mo., will be $12,500/mo. in '27 so another $4200/mo. would be nice! Love the app, had a lot of fun creating a portfolio today!
Thanks for all the hard work putting the MaxDividends! You guys have done all the heavy lifting.
And 230+ Financial Bloggers on Substack
Trusted by 65,000+ subscribers. Followed by 55,000+ dedicated readers
Alessandro MacroMornings ⭐️⭐️⭐️⭐️⭐️
“A useful substack for those that invest in stocks that pay dividends or are looking to get into such a strategy. Includes education and actionable ideas.
The European Value Investor ⭐️⭐️⭐️⭐️⭐️
“If you are interested in dividend strategies or passive income strategies, this Substack ia great! Its worth a visit“
The Long View ⭐️⭐️⭐️⭐️⭐️
“Practical dividend focus. Saving for retirement.“
The Astute Investor’s Calculus ⭐️⭐️⭐️⭐️⭐️
“Love the concept and the execution. If you are into building a portfolio that will generate ever growing income for you, subscribe to Max Dividends. I did.
Panic Drop ⭐️⭐️⭐️⭐️⭐️
“Great for helling you pick up high-yield dividend growth stocks“
And 230+ More Great Authors and Pros Are Recommending MaxDividends!
We’re in the Top 3 Financial Blogs on Substack! 💪
MaxDividends continues to be recognized for its consistent effort, commitment to quality, and the loyalty of its growing community of partners.
If you have any questions, feel free to email me at: max@maxdividends.app
FAQ
I ❤️ Dividends: Why I Believe Dividend Investing Is the Best Strategy | PDF Book
How Effective is the MaxDividends Strategy for Building Growing Passive Income
🔥 Got a question about dividends? Ask Max, your AI Dividend Assistant!
Someone's sitting in the shade today because someone planted a tree a long time ago. ― Warren Buffett.